ENGOT-OV65/KEYNOTE-B96: PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF Pembrozumab Versus Placebo Plus Paclitaxel With Optional Bevacizumab for Platinum-Resistant Recurrent Ovarian Cancer

1Nicolella Colombo, 2Robert L Coleman, 3Xiaohua Wu, 4Fatih Köse, 5Robert M Wenham, 6Alexandra Sebastianelli, 7Kosei Hasegawa, 8Emese Zsiros, 9Thibault De La Montre Rouge, 10Marzuza Bidtriki, 11Iain McNleish, 12Jalid Sehouli, 13Jacob Korach, 14Philip R Debruyne, 15Xin Weon Kim, 16Andréia C de Melo, 17Xuan Peng, 18Agata M Bogusz, 19Karín Yamada, 20Bradley J Monk, 21Department of Medicine and Surgery, University of Milan-Bicocca and Division of Gynecologic Oncology, European Institute of Oncology (IEC) IRCCS, Milan, Italy; 22Gynecologic Oncology, Texas Oncology-The Woodlands, The Woodlands, TX; 23Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 24School of Medicine, Department of Medical Oncology, Baskent University, Adana, Turkey; 25Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL; 26Gynecology Oncology, CHU de Québec-Université Laval, Québec, QC, Canada; 27Department of Gynecologic Oncology, Salta Medical University International Medical Center, Hidaka, Japan; 28Department of Gynecologic Oncology and Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY; 29Department of Medical Oncology, Centre Eugène-Maurice, Rennes, France; 30National Institute of Oncology Maria Sklodowska-Curie, Warsaw, Poland; Faculty of Medical Sciences and Health Sciences Kazimierz Pułaski University of Technology and Humanities, Radom, Poland. 31Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK; 32Department of Gynecology, Charité Universitätmedizin Berlin, Berlin, Germany; 33Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; 34Department of Medical Oncology, Kortrijk Cancer Center, AZ Griesonie, Kortrijk, Belgium; Medical Technology Research Institute (MTRI), School of Life Sciences, Anglia Ruskin University, Cambridge, UK; 35Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea, Republic of. 36Clinical Research and Technological Development Division, Instituto Nacional de Cáncer, Brazilian National Cancer Institute, Rio de Janeiro, RJ, Brazil. 37Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ. 38Global Clinical Development, Merck and Co., Inc., Rahway, NJ. 39Division of Gynecologic Oncology, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ.

10.1136/ijgc-2022-ESGO.538

Introduction/Background Despite therapeutic advances in ovarian cancer, platinum-resistant recurrent ovarian cancer remains an area of high unmet clinical need and there is an urgent need for new treatments to further improve clinical outcomes. ENGOT-ov65/KEYNOTE-B96 (NCT05116189) compares the efficacy and safety of pembrozumab plus weekly paclitaxel (± bevacizumab) versus placebo plus weekly paclitaxel (± bevacizumab) in patients with platinum-resistant recurrent ovarian cancer.

Methodology In this randomized, placebo-controlled, double-blind, phase 3 study, eligible patients are aged ≥18 years with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1–2 prior lines of systemic therapy, including at least 1 prior platinum-based therapy with ≥4 cycles in first line. Patients must have platinum-resistant disease (radiographic evidence of disease progression ≤6 months after last platinum-based therapy dose), be eligible for paclitaxel (with/without bevacizumab per investigator discretion), and have ECOG PS ≤1, radiographically evaluable disease per RECIST version 1.1, and a tumour sample for central evaluation of PD-L1 status. Approximately 616 patients will be randomized 1:1 to receive pembrozumab 400 mg IV or placebo Q6W for up to 18 cycles (~2 years) plus paclitaxel 80 mg/m² on days 1, 8, and 15 of each Q3W cycle (with/without bevacizumab 10 mg/kg Q2W per investigator discretion) until disease progression or unacceptable toxicity.

Primary endpoint is PFS per RECIST version 1.1 by investigator review. Secondary endpoints are OS, PFS per RECIST version 1.1 by blinded independent central review, safety, and patient-reported outcomes. Enrollment is ongoing.

Results N/A

Conclusion N/A

ENGOT-OV66/ESGO

CHARACTERIZATION OF EXTENDED TREATMENT BENEFIT FROM THREE PHASE 1 AND 3 CLINICAL TRIALS EXAMINING PATIENTS WITH FOLATE RECEPTOR ALPHA-POSITIVE RECURRENT OVARIAN CANCER TREATED WITH SINGLE-AGENT MIRVETUXIMAB SORAVTANSINE

1Ana Oaklin, 2Domenica Loruso, 3Amit Oza, 4Nicolella Colombo, 5Toon van Gorp, 6David O’Malley, 7Susana Banerjee, 8Conleith Murphy, 9Philip Harter, 10Gottfried Koncny, 11Marie-Christine Kaminsky, 12Michael Method, 13Jiuzhou Wang, 14Robert L Coleman, 15Michael Birrer, 16Ursula Matulonis, 17Kathleen Moore, 18Vall d’Hebron University Hospital, Barcelona, Spain; 19Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy; 20Ontario Institute for Cancer Research, Toronto, ON, Canada; 21Istituto Europeo Oncologia, Milan, Italy; 22University Hospital Leuven, Leuven, Belgium; 23James Cancer Center/The Ohio State University, Columbus, OH; 24The Institute for Cancer Research, London, UK; 25Bon Secours Hospital, Cork, Ireland; 26Klinikum Essen Mitte Evang, Essen, Germany; 27UCAL Health, Los Angeles, CA; 28GINECO/Centre Alexis Vautrin, Nancy, France; 29ImmunoGen Inc., Waltham, MA; 30US Oncology Research, The Woodlands, TX; 31University of Arkansas for Medical Sciences, Little Rock, AR; 32Dana-Farber Cancer Institute, Boston, MA; 33Stephenson Cancer Center/University of Oklahoma, Oklahoma City, OK.

10.1136/ijgc-2022-ESGO.539

Introduction Background Mirvetuxumab soravtansine (MV) is a first-in-class antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cavaeble linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent that has demonstrated significant antitumor activity in this difficult-to-treat ovarian cancer population. The objective was to characterize the patients with FRα-positive recurrent ovarian cancer who achieved extended treatment benefit (ETB); progression-free survival for >12 months) with MV monotherapy.

Methodology Retrospective pooled analysis included patients enrolled across three trials: phase 1 first-in-human, phase 3 FORWARD I, and phase 3 SORAYA. Analysis included patients with low, medium, and high FRα expression by immunohistochemistry. All patients received intravenous MV at 6 mg/kg, adjusted ideal body weight, every three weeks until disease progression or unacceptable toxicity.

Results Of the 464 patients included in the analysis, 40 ETB patients were identified: median age 63 years, median of one prior therapy, 52.5% with prior PARPi, and 60% with prior bevacizumab. ETB patients had an overall response rate of 75.0%, with 9 (22.5%) achieving a complete response and 21 (52.5%) achieving a partial response by RECIST v1.1 and demonstrated a median duration of response of 22.1 months (95% CI, 13.8–60.0; interquartile range 13.5–60.0). The most common treatment-related adverse events (TRAEs) (all grade, grade 3+) included blurred vision (60%, 0%), fatigue (50%, 2.5%), nausea (50%, 0%), and keratopathy (40%, 2.5%). Peripheral neuropathy was present in 35% (no grade 3+) and pneumonitis was present in 20% (no grade 3+). TRAEs led to dose delay or reduction in 65% and 47.5% of ETB patients, respectively, and discontinuation in six patients.
Conclusion In a pooled analysis of 464 patients, MIRV monotherapy demonstrated ETB in ~10% patients. The safety profile consisted primarily of low-grade gastrointestinal and ocular events and reinforces MIRV's potential to become a new standard of care for FRα-positive ovarian cancer.

Introduction/Background The ESGO-quality indicators (QIs) for advanced ovarian cancer (AOC) have been assessed only by few Italian centres, and data are not available on the proportion of centres reaching the score considered for a satisfactory surgical management. There is great consensus that the ERAS approach is beneficial, but there is paucity of data concerning its application in AOC. This survey was aimed at gathering detailed information on perioperative management of advanced ovarian cancer (tubal/peritoneal) patients. A survey from MITO-MaNGO groups.

Methodology A 66-item questionnaire, covering ESGO-QIs for AOC and ERAS items, was sent to MITO-MaNGO centres reporting to operate >20 AOC/year.

Results Thirty/34 questionnaires were analysed. The median ESGO-QIs score was 31.5, with 50% of centres resulting with a score ≥32 which provides satisfactory surgical management. The rates of concordance with ERAS guidelines were 46.6%, 74.1%, and 60.7%, respectively, for pre-operative, intra-operative, and post-operative items. The proportion of overall agreement was 61.3%, and with strong recommendations was 63.1%. Pre-operative diet, fasting/bowel preparation, correction of anaemia, post-operative feeding and early mobilization were the most controversial. A significant positive correlation was found between ESGO-QIs score and adherence to ERAS recommendations.

Conclusion This survey reveals a satisfactory surgical management in only half of the centres, and an at least sufficient adherence to ERAS recommendations. Higher the ESGO-QIs score stronger the adherence to ERAS recommendations, underlining the correlations between case volume, appropriate peri-operative management and quality of surgery.